SiBionics
PrivateLast Round
Series D
Dec 21, 2022
Total Funding Raised
$196.7M
Company Overview
SiBionics operates in Healthcare & Life Sciences and is based in Shenzhen. Its latest recorded funding round was a Series D round in December 2022.
SiBionics is a medical technology company that develops and markets active implantable medical devices and AI-driven solutions for chronic disease management, including continuous glucose monitoring systems.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Health IoT, Medical AI, Sensors
Business Model
B2C
Customer Profile
Hardware Sales, Hardware + Subscription
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
SiBionics Comparables
Compare SiBionics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Medtrum Technologies | 84% | |
| Abbott Laboratories | 83% | |
| DexCom | 82% |
For institutional investors. Book with your work email.
SiBionics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Dec 21, 2022 | ||||
| Series C Extension | Jan 21, 2022 | ||||
| Series C Extension | May 7, 2021 | ||||
| Series C | Dec 25, 2020 | ||||
| Series B | Oct 1, 2017 |
For institutional investors. Book with your work email.
SiBionics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Longmen Capital | Series B |
| Luxin Venture Capital Group Co., Ltd. | Series C Extension, Series C |
| Shenzhen Dachen Caizhi Venture Capital Management | Series C Extension |
| Xingzheng Innovation Capital | Series D |
| Sunshine Insurance Group | Series C |
| Source Code Capital | Series C Extension, Series C |
| CPE | Series C Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 22, 2025
Attended the EASD 2025 event to showcase diabetes solutions.
- Sep 22, 2025
Continuous Glucose Monitor (CGM) meets special control criteria for integrated systems.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventAug 31, 2026
Sibionics group explored new perspectives for automated insulin delivery at the EASD 2026 congress in Italy on Oct 5th '26.
- attends_eventAug 31, 2026
Sibionics group attends the IDF-WPR, ADC and Metabolic Diseases 2026 congress in Australia in Aug '26 and showcases sensor innovation and AI-powered glucose monitoring.
For institutional investors. Book with your work email.
SiBionics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about SiBionics's valuation, stock price, and market status.
Is SiBionics a public or private company?
SiBionics is a private company.
What is the current stock price of SiBionics?
SiBionics is a private company, so its shares have no public market price. Caplight tracks SiBionics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is SiBionics worth (valuation)?
Valuation information for SiBionics is not publicly available.
Can I buy SiBionics stock?
SiBionics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was SiBionics's last funding round?
SiBionics's most recent funding round was Series D on December 21, 2022.
Who are the main investors in SiBionics?
Key investors in SiBionics include Shenzhen Dachen Caizhi Venture Capital Management, Source Code Capital, CPE.
Will SiBionics IPO soon?
No public IPO plans have been announced for SiBionics.
How can I track SiBionics secondary market activity?
Caplight tracks bids, offers, and trades in SiBionics's shares on secondary markets.